Roche Holding Ltd · SIX:RO
Roche — Investor Presentation (2018)
49 slides from Roche's investor presentation, 2018
Slide 1: Appendix: Potential target patient populations 2018
Appendix Potential target patient populations 2018
Slide 2: Therapeutic area index
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 2
Slide 3: HER2+ early Breast Cancer
Herceptin + Perjeta, Tecentriq: HER2+ early Breast Cancer (eBC) 2018 estimates for number of patients Source: Roche/Genentech 3
Slide 4: HER2+ metastatic Breast Cancer
Perjeta, Herceptin, Kadcyla, Tecentriq: HER2+ metastatic Breast Cancer (mBC) • The target US and EU 5 population for 1L HER2+ mBC is ~19,300 patients (7,800 de novo and 11,400 adjuvant relapse) • The target US and EU 5 population for 2L-4L HER2+ mBC is ~34,900 patients (~19,700 US/~15,200 Top 5 EU)
Slide 5: Ipatasertib: HER2-/HR+ metastatic Breast Cancer
Ipatasertib: HER2-/HR+ 1L and recurrent mBC 2018 estimates for number of patients Source: Roche/Genentech; *2/3L includes HR+ patients who received chemotherapy in 1L; Patients may receive up to 7 lines of treatment, but 4L+ patients are not included; 5 Ipatasertib in collaboration with Array BioPha
Slide 6: Triple Negative Breast Cancer
Tecentriq, ipatasertib: Triple Negative Breast Cancer (TNBC) 2018 estimates for number of patients Source: Roche/Genentech; Ipatasertib in collaboration with Array BioPharma 6
Slide 7: Ovarian Cancer
Avastin: Ovarian Cancer (OC) 2018 estimates for number of patients Source: Roche/Genentech 7
Slide 8: Non Squamous Non Small Cell Lung Cancer
Tecentriq, Avastin: Non Squamous Non Small Cell Lung Cancer (NSq NSCLC) 2018 estimates for number of patients Source: Roche/Genentech 8
Slide 9: ALK+ metastatic Non Small Cell Lung Cancer
Alecensa: ALK+ metastatic Non Small Cell Lung Cancer (mNSCLC) 2018 estimates for number of patients Source: Roche/Genentech; Alecensa in collaboration with Chugai 9
Slide 10: Small Cell Lung Cancer
Tecentriq: Small Cell Lung Cancer (SCLC) 2018 estimates for number of patients Source: Roche/Genentech 10
Slide 11: Adjuvant BRAF+ Melanoma
Zelboraf: Adjuvant BRAF+ stage IIc and III Melanoma 2018 estimates for number of patients Source: Roche/Genentech; Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group 11
Slide 12: 1L BRAF+ metastatic Melanoma
Zelboraf: 1L BRAF+ metastatic Melanoma (mM) 2018 estimates for number of patients Source: Roche/Genentech; Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group 12
Slide 13: Advanced Basal Cell Carcinoma
Erivedge: Advanced Basal Cell Carcinoma (BCC) 2018 estimates for number of patients Source: Roche/Genentech 13
Slide 14: Colorectal Cancer
Avastin: Colorectal Cancer (CRC) • The target population for Avastin in 1L CRC is ~124,000 patients and in 2L CRC ~78,600 patients 2018 estimates for number of patients Source: Roche/Genentech 14
Slide 15: Adjuvant Muscle Invasive Bladder Cancer
Tecentriq: Adjuvant Muscle Invasive Bladder Cancer (MIBC) 2018 estimates for number of patients Source: Roche/Genentech 15
Slide 16: Metastatic Urothelial Bladder Cancer
Tecentriq: Metastatic Urothelial Bladder Cancer (mUBC) 2018 estimates for number of patients Source: Roche/Genentech 16
Slide 17: Renal Cell Carcinoma
Tecentriq: Renal Cell Carcinoma (RCC) 2018 estimates for number of patients Source: Roche/Genentech 17
Slide 18: Indolent Non-Hodgkin's Lymphoma
Gazyva, Rituxan: Indolent Non-Hodgkin`s Lymphoma (iNHL) 2018 estimates for number of patients Source: Roche/Genentech; Gazyva in collaboration with Biogen 18
Slide 19: Aggressive Non-Hodgkin's Lymphoma
Polatuzumab vedotin, Rituxan: Aggressive Non-Hodgkin`s Lymphoma (aNHL/DLBCL) 2018 estimates for number of patients Source: Roche/Genentech; Polatuzumab vedotin in collaboration with Seattle Genetics; DLBCL=diffuse large B-Cell Non-Hodgkin’s lymphoma; 19
Slide 20: Chronic Lymphocytic Leukemia
Gazyva, Venclexta, Rituxan: Chronic Lymphocytic Leukemia (CLL) 2018 estimates for number of patients Source: Roche/Genentech; Gazyva in collaboration with Biogen; Venclexta in collaboration with AbbVie 20
Slide 21: Acute Myeloid Leukemia
Venclexta, idasanutlin: Acute Myeloid Leukemia (AML) 2018 estimates for number of patients Source: Roche/Genentech; Venclexta in collaboration with AbbVie 21
Slide 22: Multiple Myeloma
Venclexta: Multiple Myeloma (MM) 2018 estimates for number of patients Source: Roche/Genentech; Venclexta in collaboration with AbbVie 22
Slide 23: Therapeutic area index
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 23
Slide 24: Hemlibra: Hemophilia A
Hemlibra: Hemophilia A 2018 estimates for number of patients Source: Roche/Genentech; Hemlibra in collaboration with Chugai 24
Slide 25: Therapeutic area index
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 25
Slide 26: Age-related Macular Degeneration
Faricimab, Port Delivery System (PDS), Lucentis: Age-related Macular Degeneration (AMD) 2,1m 2,0m 2018 estimates for number of patients 1,8m 1,8m 1,7m 1,6m Source: Roche/Genentech 26
Slide 27: Diabetic Macular Edema
Faricimab, Port Delivery System (PDS), Lucentis: Diabetic Macular Edema (DME) 2018 estimates for number of patients 2,4m 2,0m 1,7m 1,3m 1,2m 0,9m Source: Roche/Genentech 27
Slide 28: Retinal Vein Occlusion
Port Delivery System (PDS), Lucentis: Retinal Vein Occlusion (RVO) 2018 estimates for number of patients Source: Roche/Genentech 28
Slide 29: Therapeutic area index
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 29
Slide 30: Baloxavir marboxil: Influenza A & B
Baloxavir marboxil: Influenza A & B 2018 estimates for number of patients Source: Roche/Genentech; Baloxavir marboxil co-developed with Shionogi with Roche holding worldwide license excluding Japan and Taiwan 30
Slide 31: Therapeutic area index
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 31
Slide 32: Ocrevus: Multiple Sclerosis
2018 estimates for number of patients Ocrevus: Source: Roche/Genentech Multiple Sclerosis (MS) 2018 estimates for number of patients 32
Slide 33: Risdiplam: Spinal Muscular Atrophy
Risdiplam (RG7916): Spinal Muscular Atrophy (SMA) 2018 estimates for number of patients Source: Roche/Genentech; Risdiplam in collaboration with PTC Therapeutics and SMA Foundation 33
Slide 34: Duchenne Muscular Dystrophy
Myostatin inhibiting adnectin fusion protein (RG6206): Duchenne Muscular Dystrophy (DMD) 2018 estimates for number of patients Source: Roche/Genentech 34
Slide 35: HTT-ASO: Huntington's Disease
HTT-ASO (RG6042): Huntington’s Disease (HD) 2018 estimates for number of patients Source: Roche/Genentech; HTT-ASO licensed from IONIS Pharmaceuticals 35
Slide 36: Balovaptan: Autism Spectrum Disorder
Balovaptan (RG7314): Autism Spectrum Disorder (ASD) There are no FDA approved pharmacologic treatments for the core symptoms of ASD so today no one is treated with a pharmacologic for the core symptoms of Autism Spectrum Disorder* 2018 estimates for number of patients Source: Roche/Genentech; *Pharm
Slide 37: Alzheimer's Disease
Crenezumab, gantenerumab: Alzheimer’s Disease (AD) 2018 estimates for number of patients Source: Roche/Genentech; aMCI=amnestic mild cognitive impairment; Crenezumab in collaboration with AC Immune; Gantenerumab in collaboration with MorphoSys 37
Slide 38: Satralizumab: Neuromyelitis Optica
Satralizumab (RG6168): Neuromyelitis Optica (NMO) 2018 estimates for number of patients Source: Roche/Genentech; Clinical developpment by Chugai 38
Slide 39: Prasinezumab: Parkinson's Disease
Prasinezumab (RG7935): Parkinson’s Disease (PD) 2018 estimates for number of patients Source: Roche/Genentech; H&Y: Hoehn & Yahr scale; Prasinezumab in collaboration with Prothena 39
Slide 40: Therapeutic area index
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 40
Slide 41: Esbriet: Idiopathic Pulmonary Fibrosis
Esbriet: Idiopathic Pulmonary Fibrosis (IPF) 2018 estimates for number of patients Source: Roche/Genentech 41
Slide 42: Xolair: Moderate to severe Asthma
Xolair: Moderate to severe Asthma 2018 estimates for number of patients Source: Roche/Genentech 42
Slide 43: Rheumatoid Arthritis
Actemra , Rituxan: Rheumatoid Arthritis (RA) Global target population for Actemra and Rituxan in rheumatoid US patients treated with biologics by line arthritis is ~1.2M biologics eligible patients. of therapy (thousands) 2018 estimates for number of patients Source: Roche/Genentech; Actemra in coll
Slide 44: Systemic Juvenile Idiopathic Arthritis
Actemra: Systemic Juvenile Idiopathic Arthritis (sJIA) 2018 estimates for number of patients Source: Roche/Genentech; Actemra in collaboration with Chugai 44
Slide 45: Polyarticular Juvenile Idiopathic Arthritis
Actemra: Polyarticular Juvenile Idiopathic Arthritis (pJIA) 2018 estimates for number of patients Source: Roche/Genentech; Actemra in collaboration with Chugai 45
Slide 46: Actemra: Giant Cell Arteritis
Actemra: Giant Cell Arteritis (GCA) 2018 estimates for number of patients Source: Roche/Genentech; Actemra in collaboration with Chugai 46
Slide 47: Etrolizumab: Ulcerative Colitis
Etrolizumab: Ulcerative Colitis (UC) 2018 estimates for number of patients Source: Roche/Genentech 47
Slide 48: Etrolizumab: Crohn's Disease
Etrolizumab: Crohn’s Disease (CD) 2018 estimates for number of patients Source: Roche/Genentech 48
Slide 49: Doing now what patients need next
Doing now what patients need next